Coronary artery stents: Evaluating new designs for contemporary percutaneous intervention

Intracoronary stents have markedly improved the short‐ and long‐term safety and efficacy of percutaneous coronary intervention by improving acute gains in luminal dimensions, decreasing abrupt vessel occlusion, and reducing restenosis. At present, nearly 90% of all coronary interventions involve stenting. A variety of advances in stent technology and design have expanded the clinical application of stenting to include complex coronary lesions, multivessel disease, and small‐diameter vessels. In addition, the development of stents as drug delivery systems for antithrombotic or antiproliferative agents has the potential to expand the role of coronary stenting, and early clinical experience appears promising. The purpose of this review is to describe recent developments in stent design, examine the results of clinical trials of contemporary stents, and present future directions for investigation of new stent technologies. Cathet Cardiovasc Intervent 2002;56:562–576. © 2002 Wiley‐Liss, Inc.

[1]  N. Reifart.  The JOSTENT® Coronary Stent Range , 2001 .

[2]  J. Kjekshus,et al.  Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. , 2001, Journal of the American College of Cardiology.

[3]  A. Yeung,et al.  Prevention of Distal Embolization During Coronary Angioplasty in Saphenous Vein Grafts and Native Vessels Using Porous Filter Protection , 2001, Circulation.

[4]  A. Kastrati,et al.  Stenting for small coronary vessels: a contestable winner. , 2001, Journal of the American College of Cardiology.

[5]  Benno J. Rensing,et al.  Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.

[6]  S Doucet,et al.  Stent Placement to Prevent Restenosis After Angioplasty in Small Coronary Arteries , 2001, Circulation.

[7]  P. Guyon,et al.  Stent Placement Compared With Balloon Angioplasty for Small Coronary Arteries: In-Hospital and 6-Month Clinical and Angiographic Results , 2001, Circulation.

[8]  Y. Matsumoto,et al.  Does stent design affect probability of restenosis? A randomized trial comparing Multilink stents with GFX stents. , 2001, American heart journal.

[9]  O. Hess,et al.  Stent Coating With Titanium-Nitride-Oxide for Reduction of Neointimal Hyperplasia , 2001, Circulation.

[10]  E. Edelman,et al.  Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery , 2001, Circulation.

[11]  S. Gehman.  Increased risk of restenosis after placement of gold-coated stents. , 2001, Circulation.

[12]  A. Kastrati,et al.  Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. , 2003, Journal of the American College of Cardiology.

[13]  Elazer R. Edelman,et al.  Gold-Coated NIR Stents in Porcine Coronary Arteries , 2001, Circulation.

[14]  G. Pasterkamp,et al.  Oral Matrix Metalloproteinase Inhibition and Arterial Remodeling After Balloon Dilation: An Intravascular Ultrasound Study in the Pig , 2001, Circulation.

[15]  D. Baim,et al.  Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. , 2001, The American journal of cardiology.

[16]  C. Di Mario,et al.  Emergency Polytetrafluoroethylene-Covered Stent Implantation to Treat Coronary Ruptures , 2000, Circulation.

[17]  A. Kastrati,et al.  A Randomized Trial Comparing Stenting With Balloon Angioplasty in Small Vessels in Patients With Symptomatic Coronary Artery Disease , 2000 .

[18]  T. Meinertz,et al.  Treatment of Aortocoronary Vein Graft Lesions With Membrane-Covered Stents: A Multicenter Surveillance Trial , 2000, Circulation.

[19]  Larry S. Dean,et al.  Randomized Comparison of GR-II Stent and Palmaz-Schatz Stent for Elective Treatment of Coronary Stenoses , 2000, Circulation.

[20]  C. Di Mario,et al.  Left internal mammary artery graft perforation repair using polytetrafluoroethylene‐covered stents , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[21]  C. Di Mario,et al.  Polytetrafluoroethylene-covered stent for the treatment of narrowings in aorticocoronary saphenous vein grafts. , 2000, The American journal of cardiology.

[22]  A. Colombo,et al.  Biodegradable stents : "fulfilling the mission and stepping away". , 2000, Circulation.

[23]  H. Uehata,et al.  Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.

[24]  P. Mølstad,et al.  Stenting small coronary arteries using two second‐generation slotted tube stents: Acute and six‐month clinical and angiographic results , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[25]  W. Laskey,et al.  A stent is a stent is a stent (not) , 2000, Catheterization and cardiovascular interventions.

[26]  P. Boekstegers,et al.  Influence of stent design on 1‐year outcome after coronary stent placement: A randomized comparison of five stent types in 1,147 unselected patients , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[27]  J. Verheijen,et al.  Angioplasty : A Study in the Atherosclerotic Yucatan Micropig Metalloproteinase Inhibition Reduces Constrictive Arterial Remodeling After Balloon , 2000 .

[28]  A. Kastrati,et al.  Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. , 2000, Circulation.

[29]  A. Colombo,et al.  Multicenter registry to evaluate the efficacy of the NIROYAL stent in de novo or restenotic coronary stenosis. , 2000, The Journal of invasive cardiology.

[30]  T. Fischell.  Visible stents: all that glitters...is it gold? , 2000, The Journal of invasive cardiology.

[31]  C. Vlachopoulos,et al.  Stents covered by autologous venous grafts: feasibility and immediate and long-term results. , 2000, American heart journal.

[32]  H. Suryapranata,et al.  Multicenter evaluation of the phosphorylcholinecoated biodivYsio stent in short de novo coronary lesions: The SOPHOS study , 2000, International journal of cardiovascular interventions.

[33]  Bruce R. Brodie,et al.  Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction , 1999 .

[34]  J. Moses,et al.  Procedural and late outcomes following MULTI-LINK DUET coronary stent deployment. , 1999, The American journal of cardiology.

[35]  G. Stone,et al.  Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. , 1999, Circulation.

[36]  R. Califf,et al.  Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial , 1999, The Lancet.

[37]  E. Edelman,et al.  Stent-versus-stent equivalency trials : are some stents more equal than others? , 1999, Circulation.

[38]  K. Teo,et al.  Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). , 1999, Circulation.

[39]  C. Wegner,et al.  Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. , 1999, Journal of cardiovascular pharmacology.

[40]  S Marx,et al.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.

[41]  R. Calne,et al.  Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. , 1999, Transplantation.

[42]  J. Ferguson,et al.  Meeting highlights : highlights of the 22nd congress of the european society of cardiology. , 1999, Circulation.

[43]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[44]  R E Vlietstra,et al.  ACC Expert Consensus document on coronary artery stents. Document of the American College of Cardiology. , 1998, Journal of the American College of Cardiology.

[45]  H Shimokawa,et al.  Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. , 1998, Journal of the American College of Cardiology.

[46]  Antonio Colombo,et al.  Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.

[47]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[48]  Robert C. Eberhart,et al.  Bioresorbable Microporous Stents Deliver Recombinant Adenovirus Gene Transfer Vectors to the Arterial Wall , 1998, Annals of Biomedical Engineering.

[49]  D. Fischman,et al.  One-year follow-up of the Stent Restenosis (STRESS I) Study. , 1998, The American journal of cardiology.

[50]  R. Califf,et al.  Myonecrosis after revascularization procedures. , 1998, Journal of the American College of Cardiology.

[51]  J. Badimón,et al.  Rapamycin inhibits vascular smooth muscle cell migration. , 1996, The Journal of clinical investigation.

[52]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[53]  W Rutsch,et al.  Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. , 1996, Circulation.

[54]  P D Verdouw,et al.  Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. , 1996, Circulation.

[55]  S Sawada,et al.  Reaction of the aortic wall to six metallic stent materials. , 1995, Academic radiology.

[56]  V. Dzau,et al.  Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. , 1995, Transplantation.

[57]  S. Marx,et al.  Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. , 1995, Circulation research.

[58]  J. Forrester,et al.  1001-29 Prevention of Subacute Stent Thrombosis by Polymer-Polyethylene Oxide-Heparin Coating in the Rabbit Carotid Artery , 1995 .

[59]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[60]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[61]  S. Kaul,et al.  Assessment of Risk Area During Coronary Occlusion and Infarct Size After Reperfusion With Myocardial Contrast Echocardiography Using Left and Right Atrial Injections of Contrast , 1993, Circulation.

[62]  M. Leon,et al.  Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. , 2001, The American journal of cardiology.

[63]  K Ulm,et al.  Restenosis after coronary placement of various stent types. , 2001, The American journal of cardiology.

[64]  P. Radke,et al.  Stent coatings. , 2001, The Journal of invasive cardiology.

[65]  C. Vlachopoulos,et al.  Implantation of stents covered by autologous arterial grafts in human coronary arteries: a new technique. , 2000, The Journal of invasive cardiology.

[66]  J. M. Bloom.  Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. , 1998, The New England journal of medicine.